跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

P-023

Supelco

芬特明标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C10H15N
CAS號碼:
122-09-8
分子量：:
149.23
MDL號碼:
MFCD00059195
分類程式碼代碼:
41116107
PubChem物質ID:
329820023
NACRES:
NA.24

等級

certified reference material

品質等級

300

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

形式

single component solution

儲存溫度

2-8°C

SMILES 字串

NC(C)(C)CC1=CC=CC=C1

InChI

1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3

InChI 密鑰

DHHVAGZRUROJKS-UHFFFAOYSA-N

相關類別

一般說明

Snap-N-Spike®参比溶液，适用于通过LC-MS/MS或GC/MS进行临床毒理学或尿液药物检测。苯乙胺类似物芬特明是一种兴奋剂和厌食剂。该药物是已撤回的抗肥胖药fen-phen的成分。

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 1

閃點（°F）

49.5 °F - closed cup

閃點（°C）

9.7 °C - closed cup

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助，請聯絡 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 2

1 of 2

(±)-甲基苯丙胺标准液 溶液 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-009

(±)-甲基苯丙胺标准液 溶液

戊巴比妥标准液 溶液 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

P-010

戊巴比妥标准液 溶液

Fiona Cameron et al.
Drugs, 72(15), 2033-2042 (2012-10-09)
Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed
Prescrire international, 22(136), 61-64 (2013-04-18)
The cornerstones of treatment for obesity, and even more so for simple overweight, are dietary measures and physical exercise. There are no drugs with a favourable harm-benefit balance in this setting. A fixed-dose combination of topiramate, an antiepileptic drug, and
Two new drugs approved for obesity.
Annette M Johnson
South Dakota medicine : the journal of the South Dakota State Medical Association, 65(9), 356-357 (2012-10-17)
Eva Manakova et al.
Neuro endocrinology letters, 33 Suppl 3, 179-182 (2013-01-29)
Both, obesity as well as anorexia may be associated with infertility and other complications of pregnancy. Weight loss during pregnancy is therefore considered a risk factor. Weight loss and appetite suppressant are contraindicated during pregnancy, but the unintended exposure is
New medications for weight loss.
Melissa Murfin
JAAPA : official journal of the American Academy of Physician Assistants, 25(12), 59-60 (2013-04-23)
查看所有相關論文

條款

US EPA Method 8270 (Appendix IX): GC Analysis of Semivolatiles on Equity®-5 (30 m x 0.25 mm I.D., 0.50 μm)

US EPA Method 8270 (Appendix IX): GC Analysis of Semivolatiles on Equity®-5 (30 m x 0.25 mm I.D., 0.50 μm)

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務